IMNM Q2 2025 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+69.8% YoY

Gross Profit

$3M82.1% margin

Operating Income

-$46M-1157.6% margin

Net Income

-$43M-1080.9% margin

EPS (Diluted)

$-0.50

QoQ Revenue Growth

+37.2%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$50M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$296M

Total Liabilities

$27M

Stockholders' Equity

$269M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+69.8%
Gross Profit	$3M	$2M	+39.4%
Operating Income	-$46M	-$40M	-16.2%
Net Income	-$43M	-$36M	-20.1%